Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study

CHALLA, Balasekhara Reddy; AWEN, Bahlul Z.; CHANDU, Babu Rao; KHAGGA, Mukkanti; KOTTHAPALLI, Chandrasekhar Bannoth

doi:10.3797/scipharm.1002-07

Open AccessArticle

Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study

by

Balasekhara Reddy CHALLA

^1,2,*,

Bahlul Z. AWEN

³,

Babu Rao CHANDU

³,

Mukkanti KHAGGA

⁴ and

Chandrasekhar Bannoth KOTTHAPALLI

¹

Jawaharlal Nehru Technological University, Anantapur, Andhra Pradesh, 515002, India

²

Siddharth Institute of Pharmacy, Nalanda Educational Society, Kantepudi, Sattenapalli, Guntur, 522438, India

³

Faculty of Pharmacy, Al-Jabal Al-Gharbi University, Libya

⁴

Jawaharlal Nehru Technological University, Hyderabad, 500072, India

^*

Author to whom correspondence should be addressed.

Sci. Pharm. 2010, 78(3), 411-422; https://doi.org/10.3797/scipharm.1002-07

Submission received: 10 February 2010 / Accepted: 4 June 2010 / Published: 4 June 2010

Download Versions Notes

Abstract

A simple, sensitive, and specific LC-ESI–MS/MS method for quantification of Montelukast (MO) in human plasma using Montelukast-d6 (MOD6) as an internal standard (IS) is discussed here. Chromatographic separation was performed on YMC-pack pro C₁₈, 50 x 4.6 mm, S-3 μm column with an isocratic mobile phase composed of 10mM ammonium formate (pH 4.0):acetonitrile (20:80 v/v), at a flow-rate of 0.8 mL min⁻¹. MO and MOD6 were detected with proton adducts at m/z 586.2→568.2 and 592.3→574.2 in multiple reaction monitoring (MRM) positive mode respectively. MO and MOD6 were extracted using acetonitrile as precipitating agent. The method was validated over a linear concentration range of 1.0–800.0 ng mL⁻¹ with correlation coefficient (r²) ≥ 0.9996. The intraday precision and accuracy were within 1.91–7.10 and 98.32–99.17. The inter-day precision and accuracy were within 3.42–4.41% and 98.14–99.27% for MO. Both analytes were found to be stable throughout three freeze-thawing cycles, bench top, and autosampler stability studies. This method was utilized successfully for the analysis of plasma samples following oral administration of MO (5 mg) in 31 healthy Indian male human volunteers under fasting conditions.

Keywords: Montelukast; LC-ESI-MS/MS; Bioequivalence study

Share and Cite

MDPI and ACS Style

CHALLA, B.R.; AWEN, B.Z.; CHANDU, B.R.; KHAGGA, M.; KOTTHAPALLI, C.B. Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study. Sci. Pharm. 2010, 78, 411-422. https://doi.org/10.3797/scipharm.1002-07

AMA Style

CHALLA BR, AWEN BZ, CHANDU BR, KHAGGA M, KOTTHAPALLI CB. Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study. Scientia Pharmaceutica. 2010; 78(3):411-422. https://doi.org/10.3797/scipharm.1002-07

Chicago/Turabian Style

CHALLA, Balasekhara Reddy, Bahlul Z. AWEN, Babu Rao CHANDU, Mukkanti KHAGGA, and Chandrasekhar Bannoth KOTTHAPALLI. 2010. "Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study" Scientia Pharmaceutica 78, no. 3: 411-422. https://doi.org/10.3797/scipharm.1002-07

APA Style

CHALLA, B. R., AWEN, B. Z., CHANDU, B. R., KHAGGA, M., & KOTTHAPALLI, C. B. (2010). Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study. Scientia Pharmaceutica, 78(3), 411-422. https://doi.org/10.3797/scipharm.1002-07

Article Menu

Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI